Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Paediatr Anaesth ; 29(6): 656-657, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30907463

RESUMEN

We report the case of an 11-month-old boy with Wilm's tumor, who underwent nephrectomy. Postoperative pain was managed with a lumbar epidural for 3 days, with the formation of a persistent cerebral spinal fluid cutaneous fistula.


Asunto(s)
Anestesia Epidural/efectos adversos , Cateterismo/efectos adversos , Fístula Cutánea , Humanos , Lactante , Masculino
2.
Middle East J Anaesthesiol ; 23(4): 471-4, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27382818

RESUMEN

Long QT syndrome (LQTS) is a rare condition that in certain circumstances can lead to severe and potentially lethal cardiac arrhythmia known as Torsade de Pointes (TdP). Inhalational anesthetics are among many medications and conditions known to prolong QT and thus potentially predispose the patient to TdP. Although studies have shown that sevoflurane should be safe for the healthy patients, the situation is unclear in patients with LQTS. We present a case of 14-year-old Caucasian female with the diagnosis of LQTS who developed TdP during sevoflurane inhalational induction. At the end, an anesthetic plan for patients with LQTS will be suggested.


Asunto(s)
Síndrome de QT Prolongado/complicaciones , Éteres Metílicos/efectos adversos , Torsades de Pointes/inducido químicamente , Adolescente , Electrocardiografía , Femenino , Humanos , Sevoflurano
3.
Anesth Analg ; 115(4): 921-4, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22822188

RESUMEN

BACKGROUND: Heparin is the anticoagulant most commonly used for cardiopulmonary bypass (CPB), and the activated clotting time (ACT) is its primary monitor. In October 2009, the Food and Drug Administration changed the United States Pharmacopeia (USP) monograph for unfractionated heparin to incorporate new quality tests and a new potency assay and reference standard. This latter change was anticipated by in vitro tests to reduce heparin potency by 10% in each USP unit dose. After integration of the "new" heparin into our practice, we subjectively noticed less prolongation of the ACT with our routine heparin bolus before the initiation of CPB. We performed this investigation to provide objective evidence of a reduction in the level of anticoagulation achieved with use of the new heparin as assessed by ACT values and to document the occurrence of having an ACT below our institutional threshold before the initiation of CPB. METHODS: A retrospective chart review was performed on all children who underwent CPB at Children's Healthcare of Atlanta between July 1, 2008, and June 30, 2009, before the release of the new heparin ("old heparin" [OH] group) and between June 1, 2010, and May 31, 2011, after complete integration of the new heparin ("new heparin" [NH] group). Baseline ACTs and ACTs after the administration of 400 U/kg of heparin were recorded for both the OH and NH groups. We determined the number of patients in each group having an ACT <480 seconds after the initial heparin bolus but before the initiation of CPB. Additionally, patients were divided into 3 age groups (<1 month, 1 to 12 months, and >1 year) to analyze similar ACT changes. RESULTS: Postheparin ACTs were significantly lower in the NH group than in the OH group. There were significantly more patients having an ACT <480 seconds after the initial heparin bolus in the NH group (OH: 68 of 557 [12.2%] versus NH: 140 of 491 patients [28.5%]; P < 0.0001). The change remained significant when assessed across the age groups. CONCLUSIONS: In this investigation we provide objective evidence that the level of anticoagulation after the initial pre-CPB heparin bolus as assessed by the ACT is significantly less with use of the new heparin. This reduction remained consistent across 3 age groups and was associated with a more frequent occurrence of ACTs below our institutional threshold for the initiation of CPB. Consideration should be given to increasing the initial weight-based heparin dose administered before CPB.


Asunto(s)
Coagulación Sanguínea/efectos de los fármacos , Puente Cardiopulmonar/métodos , Heparina/administración & dosificación , Coagulación Sanguínea/fisiología , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Estudios Retrospectivos , Resultado del Tratamiento , Tiempo de Coagulación de la Sangre Total/tendencias
4.
Paediatr Anaesth ; 19(6): 618-22, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19655442

RESUMEN

The air-Q intubating laryngeal airway (ILA) is a new supraglottic airway device which may overcome some limitations inherent to the classic laryngeal mask airway for tracheal intubation. We present a case series of patients with anticipated difficult airway in whom the air-Q ILA was successfully used as a conduit for fiberoptic intubation.


Asunto(s)
Obstrucción de las Vías Aéreas/complicaciones , Intubación Intratraqueal/instrumentación , Máscaras Laríngeas , Niño , Preescolar , Diseño de Equipo , Femenino , Tecnología de Fibra Óptica , Humanos , Lactante , Intubación Intratraqueal/métodos , Masculino , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...